



## RIFM fragrance ingredient safety assessment, isocedranone, CAS Registry Number 13794-73-5

A.M. Api<sup>a</sup>, D. Belsito<sup>b</sup>, D. Botelho<sup>a</sup>, M. Bruze<sup>c</sup>, G.A. Burton Jr.<sup>d</sup>, J. Buschmann<sup>e</sup>, M. A. Cancellieri<sup>a</sup>, M.L. Dagli<sup>f</sup>, M. Date<sup>a</sup>, W. Dekant<sup>g</sup>, C. Deodhar<sup>a</sup>, A.D. Fryer<sup>h</sup>, L. Jones<sup>a</sup>, K. Joshi<sup>a</sup>, M. Kumar<sup>a</sup>, A. Lapczynski<sup>a</sup>, M. Lavelle<sup>a</sup>, I. Lee<sup>a</sup>, D.C. Liebler<sup>i</sup>, H. Moustakas<sup>a</sup>, M. Na<sup>a</sup>, T.M. Penning<sup>j</sup>, G. Ritacco<sup>a</sup>, J. Romine<sup>a</sup>, N. Sadekar<sup>a</sup>, T.W. Schultz<sup>k</sup>, D. Selechnik<sup>a</sup>, F. Siddiqi<sup>a</sup>, I.G. Sipes<sup>l</sup>, G. Sullivan<sup>a,\*</sup>, Y. Thakkar<sup>a</sup>, Y. Tokura<sup>m</sup>

<sup>a</sup> Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

<sup>b</sup> Member Expert Panel, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

<sup>c</sup> Member Expert Panel, Malmo University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmo, SE, 20502, Sweden

<sup>d</sup> Member Expert Panel, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 58109, USA

<sup>e</sup> Member Expert Panel, Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Strasse 1, 30625, Hannover, Germany

<sup>f</sup> Member Expert Panel, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. Dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

<sup>g</sup> Member Expert Panel, University of Wuerzburg, Department of Toxicology, Versbacher Str. 9, 97078, Würzburg, Germany

<sup>h</sup> Member Expert Panel, Oregon Health Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

<sup>i</sup> Member Expert Panel, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

<sup>j</sup> Member of Expert Panel, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

<sup>k</sup> Member Expert Panel, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN, 37996-4500, USA

<sup>l</sup> Member Expert Panel, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA

<sup>m</sup> Member Expert Panel, The Journal of Dermatological Science (JDS), Editor-in-Chief, Professor and Chairman, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

### ARTICLE INFO


Handling editor: Domingo

Version: 071621. Initial publication. All fragrance materials are evaluated on a five-year rotating basis. Revised safety assessments are published if new relevant data become available. Open access to all RIFM Fragrance Ingredient

(continued on next column)

(continued)

Safety Assessments is here: [fragrancesafetyresource.elsevier.com](http://fragrancesafetyresource.elsevier.com).  
Name: Isocedranone  
CAS Registry Number: 13794-73-5



\* Corresponding author.

E-mail address: [gsullivan@rifm.org](mailto:gsullivan@rifm.org) (G. Sullivan).

<https://doi.org/10.1016/j.fct.2021.112529>

Received 16 July 2021; Accepted 29 August 2021

Available online 1 September 2021

0278-6915/© 2021 Elsevier Ltd. All rights reserved.

(continued)

Abbreviation/Definition List:	
<b>2-Box Model</b>	- A RIFM, Inc. Proprietary <i>in silico</i> tool used to calculate fragrance air exposure concentration
<b>AF</b>	- Assessment Factor
<b>BCF</b>	- Bioconcentration Factor
<b>CNIH</b>	- Confirmation of No Induction in Humans test. A human repeat insult patch test that is performed to confirm an already determined safe use level for fragrance ingredients (Na et al., 2020)
<b>Creme RIFM Model</b>	- The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015a, 2017) compared to a deterministic aggregate approach
<b>DEREK</b>	- Derek Nexus is an <i>in silico</i> tool used to identify structural alerts
<b>DRF</b>	- Dose Range Finding
<b>DST</b>	- Dermal Sensitization Threshold
<b>ECHA</b>	- European Chemicals Agency
<b>ECOSAR</b>	- Ecological Structure-Activity Relationships Predictive Model
<b>EU</b>	- Europe/European Union
<b>GLP</b>	- Good Laboratory Practice
<b>IFRA</b>	- The International Fragrance Association
<b>LOEL</b>	- Lowest Observable Effect Level
<b>MOE</b>	- Margin of Exposure
<b>MPPD</b>	- Multiple-Path Particle Dosimetry. An <i>in silico</i> model for inhaled vapors used to simulate fragrance lung deposition
<b>NA</b>	- North America
<b>NESIL</b>	- No Expected Sensitization Induction Level
<b>NOAEC</b>	- No Observed Adverse Effect Concentration
<b>NOAEL</b>	- No Observed Adverse Effect Level
<b>NOEC</b>	- No Observed Effect Concentration
<b>NOEL</b>	- No Observed Effect Level
<b>OECD</b>	- Organisation for Economic Co-operation and Development
<b>OECD TG</b>	- Organisation for Economic Co-operation and Development Testing Guidelines
<b>PBT</b>	- Persistent, Bioaccumulative, and Toxic
<b>PEC/PNEC</b>	- Predicted Environmental Concentration/Predicted No Effect Concentration
<b>Perfumery</b>	- In this safety assessment, perfumery refers to fragrances made by a perfumer used in consumer products only. The exposures reported in the safety assessment include consumer product use but do not include occupational exposures
<b>QRA</b>	- Quantitative Risk Assessment
<b>QSAR</b>	- Quantitative Structure-Activity Relationship
<b>REACH</b>	- Registration, Evaluation, Authorisation, and Restriction of Chemicals
<b>RfD</b>	- Reference Dose
<b>RIFM</b>	- Research Institute for Fragrance Materials
<b>RQ</b>	- Risk Quotient
<b>Statistically Significant</b>	- Statistically significant difference in reported results as compared to controls with a $p < 0.05$ using appropriate statistical test
<b>TTC</b>	- Threshold of Toxicological Concern
<b>UV/Vis spectra</b>	- Ultraviolet/Visible spectra
<b>VCF</b>	- Volatile Compounds in Food
<b>VoU</b>	- Volume of Use
<b>vPvB</b>	- (very) Persistent, (very) Bioaccumulative
<b>WoE</b>	- Weight of Evidence

#### The Expert Panel for Fragrance Safety\* concludes that this material is safe as described in this safety assessment.

This safety assessment is based on the RIFM Criteria Document (Api, 2015), which should be referred to for clarifications. Each endpoint discussed in this safety assessment includes the relevant data that were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM Database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

\*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

#### Summary: The existing information supports the use of this material as described in this safety assessment.

Isocedranone was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, and environmental safety. Data from read-across analog

(continued)

isolongifolene ketone (CAS # 23787-90-8) show that isocedranone is not expected to be genotoxic. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the Threshold of Toxicological Concern (TTC) for a Cramer Class III material, and the exposure to isocedranone is below the TTC (0.0015 mg/kg/day, 0.0015 mg/kg/day, and 0.47 mg/day, respectively). Data from read-across analog isolongifolene ketone (CAS # 23787-90-8) provided isocedranone a No Expected Sensitization Induction Level (NESIL) of 9000  $\mu\text{g}/\text{cm}^2$  for the skin sensitization endpoint. The phototoxicity/photoallergenicity endpoints were evaluated based on ultraviolet/visible spectra (UV/Vis) spectra; isocedranone is not expected to be phototoxic/photoallergenic. The environmental endpoints were evaluated; isocedranone was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are  $< 1$ .

#### Human Health Safety Assessment

**Genotoxicity:** Not expected to be genotoxic. (RIFM, 2014b; RIFM, 2014c)

**Repeated Dose Toxicity:** No NOAEL available. Exposure is below the TTC.

**Reproductive Toxicity:** No NOAEL available. Exposure is below the TTC.

**Skin Sensitization:** NESIL = 9000  $\mu\text{g}/\text{cm}^2$ . (RIFM, 2018)

**Phototoxicity/Photoallergenicity:** Not expected to be phototoxic/photoallergenic. (UV/Vis Spectra, RIFM Database)

**Local Respiratory Toxicity:** No NOAEC available. Exposure is below the TTC.

#### Environmental Safety Assessment

##### Hazard Assessment:

**Persistence:** Screening-level: 2.3 (BIOWIN 3) (EPI Suite v4.11; US EPA, 2012a)

**Bioaccumulation:** Screening-level: 421.5 L/kg (EPI Suite v4.11; US EPA, 2012a)

**Ecotoxicity:** Screening-level: Fish LC50: 2.068 mg/L (RIFM Framework; Salvito, 2002)

**Conclusion:** Not PBT or vPvB as per IFRA Environmental Standards

##### Risk Assessment:

**Screening-level:** PEC/PNEC (North America and Europe)  $< 1$  (RIFM Framework; Salvito, 2002)

**Critical Ecotoxicity Endpoint:** Fish LC50: 2.068 mg/L (RIFM Framework; Salvito, 2002)

**RIFM PNEC is:** 0.00268  $\mu\text{g}/\text{L}$

• **Revised PEC/PNECs (2015 IFRA VoU):** North America and Europe: Not applicable; cleared at the screening-level

## 1. Identification

- 1. Chemical Name:** Isocedranone
- 2. CAS Registry Number:** 13794-73-5
- 3. Synonyms:** Cedran-9-one; [3R-(3 $\alpha$ ,3 $\alpha\beta$ ,6 $\alpha$ ,7 $\beta$ ,8 $\alpha\alpha$ )]-Hexahydro-3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5(4H)-one; 1H-3a,7-Methanoazulen-5(4H)-one, hexahydro-3,6,8,8-tetramethyl-, [3R-(3 $\alpha$ ,3 $\alpha\beta$ ,6 $\alpha$ ,7 $\beta$ ,8 $\alpha\alpha$ )]-; 3,6,8,8-Tetramethylhexahydro-1H-3a,7-methanoazulene-5(4H)-one; Cedralon; Isocedranone
- 4. Molecular Formula:** C<sub>15</sub>H<sub>24</sub>O
- 5. Molecular Weight:** 220.35
- 6. RIFM Number:** 5411
- 7. Stereochemistry:** 3R-(3 $\alpha$ ,3 $\alpha\beta$ ,6 $\alpha$ ,7 $\beta$ ,8 $\alpha\alpha$ ) isomer specified. Five chiral centers and 25 total stereoisomers possible.

## 2. Physical data

- 1. Boiling Point:** 286.38 °C (EPI Suite)
- 2. Flash Point:** Not Available
- 3. Log K<sub>OW</sub>:** 4.48 (EPI Suite)
- 4. Melting Point:** 74.1 °C (EPI Suite)
- 5. Water Solubility:** 5.088 mg/L (EPI Suite)
- 6. Specific Gravity:** Not Available
- 7. Vapor Pressure:** 0.00134 mm Hg at 20 °C (EPI Suite v4.0), 0.00244 mm Hg at 25 °C (EPI Suite)

(continued on next column)

8. **UV Spectra:** No absorbance between 290 and 700 nm; molar absorption coefficient is below the benchmark ( $1000 \text{ L mol}^{-1} \cdot \text{cm}^{-1}$ )
9. **Appearance/Organoleptic:** Not Available

### 3. Volume of use (worldwide band)

1. <0.1 metric ton per year (IFRA, 2015)

### 4. Exposure to fragrance ingredient (Creme RIFM Aggregate Exposure Model v1.0)

1. **95th Percentile Concentration in Hydroalcohols:** 0.048% (RIFM, 2014a)
2. **Inhalation Exposure\*:** 0.0000014 mg/kg/day or 0.000098 mg/day (RIFM, 2014a)
3. **Total Systemic Exposure\*\*:** 0.00089 mg/kg/day (RIFM, 2014a)

\*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM Aggregate Exposure Model (Comiskey, 2015, 2017; Safford, 2015, 2017).

\*\*95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section IV. It is derived from concentration survey data in the Creme RIFM Aggregate Exposure Model and includes exposure via dermal, oral, and inhalation routes whenever the fragrance ingredient is used in products that include these routes of exposure (Comiskey, 2015, 2017; Safford, 2015, 2017).

### 5. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

### 6. Computational toxicology evaluation

1. **Cramer Classification:** Class III, High\* (Expert Judgment)

Expert Judgment	Toxtree v3.1	OECD QSAR Toolbox v4.2
III	III	I

\*See the Appendix below for details.

2. Analogs Selected:

- a. **Genotoxicity:** Isolongifolene ketone (CAS # 23787-90-8)
- b. **Repeated Dose Toxicity:** None
- c. **Reproductive Toxicity:** None
- d. **Skin Sensitization:** Isolongifolene ketone (CAS # 2387-90-8)
- e. **Phototoxicity/Photoallergenicity:** None
- f. **Local Respiratory Toxicity:** None
- g. **Environmental Toxicity:** None
3. Read-across Justification: See Appendix below

### 7. Metabolism

Not considered for this risk assessment and therefore not reviewed except where it may pertain in specific endpoint sections as discussed below.

### 8. Natural occurrence

Isocedranone is not reported to occur in foods by the VCF\*.

\*VCF Volatile Compounds in Food: Database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that have been found in natural (processed) food products. Includes FEMA

GRAS and EU-Flavis data.

### 9. REACH dossier

Pre-registered for 2010; no dossier available as of 07/16/21.

### 10. Conclusion

The maximum acceptable concentrations<sup>a</sup> in finished products for isolongifolene ketone are detailed below.

IFRA Category <sup>b</sup>	Description of Product Type	Maximum Acceptable Concentrations <sup>a</sup> in Finished Products (%)
1	Products applied to the lips (lipstick)	0.69
2	Products applied to the axillae	0.21
3	Products applied to the face/body using fingertips	4.1
4	Products related to fine fragrances	3.9
5A	Body lotion products applied to the face and body using the hands (palms), primarily leave-on	0.98
5B	Face moisturizer products applied to the face and body using the hands (palms), primarily leave-on	0.98
5C	Hand cream products applied to the face and body using the hands (palms), primarily leave-on	0.98
5D	Baby cream, oil, talc	0.98
6	Products with oral and lip exposure	2.3
7	Products applied to the hair with some hand contact	7.9
8	Products with significant anogenital exposure (tampon)	0.41
9	Products with body and hand exposure, primarily rinse-off (bar soap)	7.5
10A	Household care products with mostly hand contact (hand dishwashing detergent)	27
10B	Aerosol air freshener	27
11	Products with intended skin contact but minimal transfer of fragrance to skin from inert substrate (feminine hygiene pad)	15
12	Other air care products not intended for direct skin contact, minimal or insignificant transfer to skin	No restriction

Note: <sup>a</sup>Maximum acceptable concentrations for each product category are based on the lowest maximum acceptable concentrations (based on systemic toxicity, skin sensitization, or any other endpoint evaluated in this safety assessment). For isolongifolene ketone, the basis was the skin sensitization NESIL of 9000  $\mu\text{g}/\text{cm}^2$ . <sup>b</sup>For a description of the categories, refer to the IFRA RIFM Information Booklet (<https://www.rifm.org/downloads/RIFM-IFRA%20Guidance-for-the-use-of-IFRA-Standards.pdf>).

<sup>c</sup>Calculations by Creme RIFM Aggregate Exposure Model v3.0.5.

### 11. Summary

#### 11.1. Human health endpoint summaries

##### 11.1.1. Genotoxicity

Based on the current existing data and use levels, isocedranone does not present a concern for genetic toxicity.

**11.1.1.1. Risk assessment.** Isocedranone was assessed in the BlueScreen assay and found negative for both cytotoxicity (positive: <80% relative cell density) and genotoxicity, with and without metabolic activation (RIFM, 2013). BlueScreen is a human cell-based assay for measuring the genotoxicity and cytotoxicity of chemical compounds and mixtures. Additional assays on a more reactive read-across material were considered to fully assess the potential mutagenic or clastogenic effects of the target material.

There are no data assessing the mutagenic and clastogenic activity of isocedranone; however, read-across can be made to isolongifolene ketone (CAS # 23787-90-8; see Section VI). The mutagenic activity of isolongifolene ketone has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and *Escherichia coli* strain WP2uvrA were treated with isolongifolene ketone in solvent dimethyl sulfoxide (DMSO) at concentrations up to 5000 µg/plate. No increases in the mean number of revertant colonies were observed at any tested concentration in the presence or absence of S9 (RIFM, 2014b). Under the conditions of the study, isolongifolene ketone was not mutagenic in the Ames test, and this can be extended to isocedranone.

The clastogenic activity of isolongifolene ketone was evaluated in an *in vitro* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 487. Human peripheral blood lymphocytes were treated with isolongifolene ketone in DMSO at concentrations up to 2205 µg/mL in the dose range finding (DRF) study. Micronuclei analysis in the main study was conducted up to 275 µg/mL in the presence and absence of S9 for 3 h and in the absence of metabolic activation for 24 h. Isolongifolene ketone did not induce binucleated cells with micronuclei when tested up to cytotoxic levels in either the presence or absence of an S9 activation system (RIFM, 2014c). Under the conditions of the study, isolongifolene ketone was considered to be non-clastogenic in the *in vitro* micronucleus test, and this can be extended to isocedranone.

Based on the available data, isolongifolene ketone does not present a concern for genotoxic potential, and this can be extended to isocedranone.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/09/21.

#### 11.1.2. Repeated dose toxicity

There are no repeated dose toxicity data on isocedranone or on any read-across materials. The total systemic exposure to isocedranone is below the TTC for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

**11.1.2.1. Risk assessment.** There are no repeated dose toxicity data on isocedranone or on any read-across materials that can be used to support the repeated dose toxicity endpoints. The total systemic exposure (0.89 µg/kg/day) is below the TTC for isocedranone (1.5 µg/kg/day; Kroes, 2007) for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/03/21.

#### 11.1.3. Reproductive toxicity

There are no reproductive toxicity data on isocedranone or on any read-across materials. The total systemic exposure to isocedranone is below the TTC for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

**11.1.3.1. Risk assessment.** There are no reproductive toxicity data on isocedranone or on any read-across materials that can be used to support the reproductive toxicity endpoint. The total systemic exposure to isocedranone (0.89 µg/kg/day) is below the TTC (1.5 µg/kg/day; Kroes, 2007; Laufersweiler, 2012) for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/24/21.

#### 11.1.4. Skin sensitization

Based on the existing data and read-across material isolongifolene ketone (CAS # 23787-90-8), isocedranone is considered a skin sensitizer with a defined NESIL of 9000 µg/cm<sup>2</sup>.

**11.1.4.1. Risk assessment.** Limited skin sensitization studies are available for isocedranone. Based on the existing data and read-across material isolongifolene ketone (CAS # 2387-90-8; see Section VI), isocedranone is considered a skin sensitizer. The chemical structure of the target material isocedranone indicates that it would be expected to react directly with skin proteins (OECD Toolbox v4.2). The chemical structure of the read-across material isolongifolene ketone indicates that it would not be expected to react directly with skin proteins (Roberts et al., 2007; Toxtree v3.1.0; OECD Toolbox v4.2). Read-across material isolongifolene ketone led to a 14.9% average depletion of cysteine- and lysine-peptide, indicating it would react directly with skin proteins. However, further investigation using high-resolution LC-MS showed that the depletion is likely attributed to the peptide oxidation and peptide dimer formation. The study concluded that read-across material isolongifolene ketone is not directly peptide-reactive (RIFM, 2016a). In 2 murine local lymph node assays (LLNAs), read-across material isolongifolene ketone was found to be sensitizing with an EC3 value of 36.5% (9125 µg/cm<sup>2</sup>) and EC1.6 of 4.65% (1162.5 µg/cm<sup>2</sup>), respectively (RIFM, 2016b; RIFM, 2016c). In guinea pigs, a maximization test with isocedranone did not produce any reactions indicative of sensitization (RIFM, 2002). In a Confirmation of No Induction in Humans test (CNIH), no reactions indicative of sensitization were observed in 110 subjects at 7.7% (9090 µg/cm<sup>2</sup>) of read-across material isolongifolene ketone in ethanol:DEP (1:3) (RIFM, 2018). Additionally, no reactions indicative of skin sensitization were observed in the CNIH up to 6.25% (4845 µg/cm<sup>2</sup>) read-across material isolongifolene ketone in alcohol SDA 39C (RIFM, 1989a; RIFM, 1989b; RIFM, 1973a; RIFM, 1973b). Similarly, no reactions indicative of sensitization were observed in human maximization tests up to 10% (6900 µg/cm<sup>2</sup>) of the read-across material isolongifolene ketone in petrolatum (RIFM, 1982; RIFM, 1980; RIFM, 1977a; RIFM, 1977b).

Based on the available data on read-across material isolongifolene ketone, summarized in Table 1, isocedranone is considered to be a weak skin sensitizer with a defined NESIL of 9000 µg/cm<sup>2</sup>. Section X provides the maximum acceptable concentrations in finished products, which take into account skin sensitization and application of the Quantitative Risk Assessment (QRA2) described by Api et al. (RIFM, 2020).

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/24/21.

**Table 1**

Data summary for isolongifolene ketone as read-across material for isocedranone.

LLNA Weighted Mean EC3 Value µg/cm <sup>2</sup> (No. Studies)	Potency Classification Based on Animal Data <sup>a</sup>	Human Data			
		NOEL-CNIH (Induction) µg/cm <sup>2</sup>	NOEL-HMT (Induction) µg/cm <sup>2</sup>	LOEL <sup>b</sup> (Induction) µg/cm <sup>2</sup>	WoE NESIL <sup>c</sup> µg/cm <sup>2</sup>
9125 [1]	Weak	9090	6000	NA	9000

NOEL = No observed effect level; CNIH = Confirmation of No Induction in Humans test; HMT = Human Maximization Test; LOEL = lowest observed effect level; NA = Not Available.

<sup>a</sup> Based on animal data using classification defined in ECETOC, Technical Report No. 87, 2003.

<sup>b</sup> Data derived from CNIH or HMT.

<sup>c</sup> WoE NESIL limited to 2 significant figures.

### 11.1.5. Phototoxicity/photoallergenicity

Based on the available UV/Vis spectra, isocedranone would not be expected to present a concern for phototoxicity or photoallergenicity.

**11.1.5.1. Risk assessment.** There are no phototoxicity studies available for isocedranone in experimental models. UV/Vis absorption spectra indicate no absorption between 290 and 700 nm. The corresponding molar absorption coefficient is below the benchmark of concern for phototoxicity and photoallergenicity (Henry, 2009). Based on the lack of absorbance, isocedranone does not present a concern for phototoxicity or photoallergenicity.

**11.1.5.2. UV spectra analysis.** UV/Vis absorption spectra (OECD TG 101) were obtained. The spectra indicate no absorbance in the range of 290–700 nm. The molar absorption coefficient is below the benchmark of concern for phototoxic effects,  $1000 \text{ L mol}^{-1} \cdot \text{cm}^{-1}$  (Henry, 2009).

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/03/21.

### 11.1.6. Local Respiratory Toxicity

The margin of exposure could not be calculated due to a lack of appropriate data. The exposure level for isocedranone is below the Cramer Class III TTC value for inhalation exposure local effects.

**11.1.6.1. Risk assessment.** There are no inhalation data available on isocedranone. Based on the Creme RIFM Model, the inhalation exposure is 0.000098 mg/day. This exposure is 4796 times lower than the Cramer Class III TTC value of 0.47 mg/day (based on human lung weight of 650 g; Carthew, 2009); therefore, the exposure at the current level of use is deemed safe.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 06/24/21.

## 11.2. Environmental endpoint summary

### 11.2.1. Screening-level assessment

A screening-level risk assessment of isocedranone was performed following the RIFM Environmental Framework (Salvito, 2002), which provides 3 tiered levels of screening for aquatic risk. In Tier 1, only the material's regional VoU, its log  $K_{ow}$ , and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in Salvito et al. (2002). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model (US EPA, 2012b), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegradation and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA Volume of Use Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, isocedranone was identified as a fragrance material with no potential to present a possible risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1).

A screening-level hazard assessment using EPI Suite v4.11 (US EPA, 2012a) did not identify isocedranone as possibly persistent or bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent and bioaccumulative and toxic, or very persistent and very bioaccumulative as defined in the Criteria Document (Api, 2015). As noted in the Criteria Document, the screening criteria

applied are the same as those used in the EU for REACH (ECHA, 2012). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF  $\geq 2000 \text{ L/kg}$ . Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11).

### 11.2.2. Risk assessment

Based on the current VoU (2015), isocedranone does not present a risk to the aquatic compartment in the screening-level assessment.

**11.2.2.1. Biodegradation.** No data available.

**11.2.2.2. Ecotoxicity.** No data available.

**11.2.2.3. Other available data.** Isocedranone has been registered under REACH and no additional data is available at this time.

### 11.2.3. Risk assessment refinement

Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in  $\mu\text{g/L}$ ).

Endpoints used to calculate PNEC are underlined.

Exposure information and PEC calculation (following RIFM Framework: Salvito, 2002).

Exposure	Europe (EU)	North America (NA)
Log $K_{ow}$ Used	4.48	4.48
Biodegradation Factor Used	0	0
Dilution Factor	3	3
Regional Volume of Use Tonnage Band	<1	<1
<b>Risk Characterization: PEC/PNEC</b>	<b>&lt;1</b>	<b>&lt;1</b>

Based on available data, the RQ for this material is < 1. No additional assessment is necessary.

The RIFM PNEC is 0.00268  $\mu\text{g/L}$ . The revised PEC/PNECs for EU and NA are not applicable. The material was cleared at the screening-level; therefore, it does not present a risk to the aquatic environment at the current reported volumes of use.

**Literature Search and Risk Assessment Completed On:** 06/25/21.

## 12. Literature Search\*

- **RIFM Database:** Target, Fragrance Structure-Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <http://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox:** <https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm>
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubMed:** <http://www.ncbi.nlm.nih.gov/pubmed>
- **National Library of Medicine's Toxicology Information Services:** <http://toxnet.nlm.nih.gov/>
- **IARC:** <http://monographs.iarc.fr>
- **OECD SIDS:** <http://webnet.oecd.org/hpv/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>

	LC50 (Fish) (mg/L)	EC50 (Daphnia) (mg/L)	EC50 (Algae) (mg/L)	AF	PNEC (µg/L)	Chemical Class
RIFM Framework Screening-level (Tier 1)	<u>2.068</u>	X	X	1000000	0.00268	X

- **US EPA HPVIS:** [https://ofmpub.epa.gov/opthpv/public\\_search\\_publicdetails?submission\\_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User\\_title=DetailQuery%20Results&EndPointRpt=Y#submission](https://ofmpub.epa.gov/opthpv/public_search_publicdetails?submission_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User_title=DetailQuery%20Results&EndPointRpt=Y#submission)
- **Japanese NITE:** <http://www.safe.nite.go.jp/english/db.html>
- **Japan Existing Chemical Data Base (JECDB):** [http://dra4.nihs.go.jp/mhlw\\_data/jsp/SearchPageENG.jsp](http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp)
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://chem.nlm.nih.gov/chemidplus/>

Search keywords: CAS number and/or material names.

\*Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list. The

links listed above were active as of 07/16/21.

#### Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. RIFM staff are employees of the Research Institute for Fragrance Materials, Inc. (RIFM). The Expert Panel receives a small honorarium for time spent reviewing the subject work.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fct.2021.112529>.

#### Appendix

##### Read-across Justification

##### Methods



The read-across analog was identified following the strategy for structuring and reporting a read-across prediction of toxicity as described in Schultz et al. (2015). The strategy is also consistent with the guidance provided by OECD within Integrated Approaches for Testing and Assessment (OECD, 2015) and the European Chemicals Agency read-across assessment framework (ECHA, 2017).

- First, materials were clustered based on their structural similarity. Second, data availability and data quality on the selected cluster were examined. Third, appropriate read-across analogs from the cluster were confirmed by expert judgment.
- Tanimoto structure similarity scores were calculated using FCFC4 fingerprints (Rogers and Hahn, 2010).
- The physical–chemical properties of the target material and the read-across analogs were calculated using EPI Suite v4.11 (US EPA, 2012a).
- $J_{max}$  values were calculated using RIFM's Skin Absorption Model (SAM). The parameters were calculated using the consensus model (Shen et al., 2014).
- DNA binding, mutagenicity, genotoxicity alerts, and oncologic classification predictions were generated using OECD QSAR Toolbox v4.2 (OECD, 2018).
- ER binding and repeat dose categorization were generated using OECD QSAR Toolbox v4.2 (OECD, 2018).
- Developmental toxicity was predicted using CAESAR v2.1.7 (Cassano et al., 2010).
- Protein binding was predicted using OECD QSAR Toolbox v4.2 (OECD, 2018), and skin sensitization was predicted using Toxtree.
- The major metabolites for the target material and read-across analogs were determined and evaluated using OECD QSAR Toolbox v4.2 (OECD, 2018).

	Target Material	Read-across Material
Principal Name	Isocedranone	Isolongifolene ketone
CAS No.	13794-73-5	23787-90-8
Structure		

(continued on next page)

(continued)

	Target Material	Read-across Material
		
Similarity (Tanimoto Score)		0.85
Read-across Endpoint		<ul style="list-style-type: none"> <li>• Skin sensitization</li> <li>• Genotoxicity</li> </ul>
Molecular Formula	C <sub>15</sub> H <sub>24</sub> O	C <sub>15</sub> H <sub>24</sub> O
Molecular Weight	220.35	220.35
Melting Point (°C, EPI Suite)	74.10	79.51
Boiling Point (°C, EPI Suite)	286.38	282.66
Vapor Pressure (Pa @ 25°C, EPI Suite)	0.325	0.346
Log K <sub>OW</sub> (KOWWIN v1.68 in EPI Suite)	4.48	3.81
Water Solubility (mg/L, @ 25°C, WSKOW v1.42 in EPI Suite)	1.29E+001	18.94
J <sub>max</sub> (µg/cm <sup>2</sup> /h, SAM)	2.153	1.514
Henry's Law (Pa·m <sup>3</sup> /mol, Bond Method, EPI Suite)	1.409E+001	1.29E+001
<b>Genotoxicity</b>		
DNA Binding (OASIS v1.4, QSAR Toolbox v4.2)	• No alert found	• No alert found
DNA Binding (OECD QSAR Toolbox v4.2)	• No alert found	• No alert found
Carcinogenicity (ISS)	• Non-Carcinogen (low reliability)	• Non-Carcinogen (low reliability)
DNA Binding (Ames, MN, CA, OASIS v1.1)	• No alert found	• No alert found
<i>In Vitro</i> Mutagenicity (Ames, ISS)	• No alert found	• No alert found
<i>In Vivo</i> Mutagenicity (Micronucleus, ISS)	• No alert found	• No alert found
Oncologic Classification	• Not classified	• Not classified
<b>Skin Sensitization</b>		
Protein Binding (OASIS v1.1)	• No alert found	• No alert found
Protein Binding (OECD)	• No alert found	• No alert found
Protein Binding Potency	• Not possible to classify according to these rules (GSH)	• Not possible to classify according to these rules (GSH)
Protein Binding Alerts for Skin Sensitization (OASIS v1.1)	• No alert found	• Nucleophilic addition Nucleophilic addition >> Addition to carbon-hetero double bonds Nucleophilic addition >> Addition to carbon-hetero double bonds >> Ketones
Skin Sensitization Reactivity Domains (Toxtree v2.6.13)	• No alert found	• No alert found
<b>Metabolism</b>		
Rat Liver S9 Metabolism Simulator and Structural Alerts for Metabolites (OECD QSAR Toolbox v4.2)	• See Supplemental Data 1	• See Supplemental Data 2

### Summary

There are insufficient toxicity data on isocedranone (CAS # 13794-73-5). Hence, *in silico* evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, physical-chemical properties, and expert judgment, isolongifolene ketone (CAS # 23787-90-8) was identified as a read-across analog with sufficient data for toxicological evaluation.

### Conclusions

- Isolongifolene ketone (CAS # 23787-90-8) was used as a read-across analog for the target material isocedranone (CAS # 13794-73-5) for the skin sensitization and genotoxicity endpoints.
  - o The target material and the read-across analog are structurally similar and belong to a class of fused multicyclic ketones.
  - o The target material and the read-across analog share a fused tricyclic ketone structure. Both substances share the same empirical chemical formula.
  - o The key difference between the target material and the read-across analog is the position of the methyl groups. This structural difference is toxicologically insignificant.
  - o Similarity between the target material and the read-across analog is indicated by the Tanimoto score. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
  - o The physical-chemical properties of the target material and the read-across analog are sufficiently similar to enable comparison of their toxicological properties.
  - o According to the OECD QSAR Toolbox v4.2, structural alerts for toxicological endpoints are consistent between the target material and the read-across analog.
  - o *In silico* alerts are consistent with data.

- o The target material and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
- o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.

#### Explanation of Cramer Classification

Due to potential discrepancies between the current *in silico* tools (Bhatia et al., 2015), the Cramer Class of the target material was determined using expert judgment, based on the Cramer decision tree.

- Q1. Normal constituent of the body? No
- Q2. Contains functional groups associated with enhanced toxicity? No
- Q3. Contains elements other than C, H, O, N, and divalent S? No
- Q5. Simply branched aliphatic hydrocarbon or a common carbohydrate? No
- Q6. Benzene derivative with certain substituents? No
- Q7. Heterocyclic? No
- Q16. Common terpene? (see Cramer et al., 1978 for detailed explanation) No
- Q17. Readily hydrolyzed to a common terpene? No
- Q19. Open chain? No
- Q23. Aromatic? No
- Q24. Monocarbocyclic with simple substituents? No
- Q25. Cyclopropane (see explanation in Cramer et al., 1978)? No
- Q26. Monocycloalkanone or a bicyclo compound? No
- Q22. A common component of food? No
- Q33. Has sufficient number of sulfonate or sulfamate groups for every 20 or fewer carbon atoms, without any free primary amines except those adjacent to the sulphonate or sulphamate? No. Class III (Class High)

#### References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the Research Institute for fragrance materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. *Food Chem. Toxicol.* 82, S1–S19.
- Bhatia, S., Schultz, T., Roberts, D., Shen, J., Kromidas, L., Api, A.M., 2015. Comparison of cramer classification between toxtree, the OECD QSAR Toolbox and expert judgment. *Regul. Toxicol. Pharmacol.* 71 (1), 52–62.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food Chem. Toxicol.* 47 (6), 1287–1295.
- Cassano, A., Manganaro, A., Martin, T., Young, D., Piclin, N., Pintore, M., Bigoni, D., Benfenati, E., 2010. CAESAR models for developmental toxicity. *Chem. Cent. J.* (4 Suppl. 1), S4.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regul. Toxicol. Pharmacol.* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regul. Toxicol. Pharmacol.* 88, 144–156.
- Cramer, G.M., Ford, R.A., Hall, R.L., 1978. Estimation of toxic hazard—a decision tree approach. *Food Chem. Toxicol.* 16 (3), 255–276.
- ECHA, 2012. Guidance on Information Requirements and Chemical Safety Assessment Chapter R.11: PBT Assessment, November 2012 v1.1. <http://echa.europa.eu/>.
- ECHA, 2017. Read-across Assessment Framework (RAAF). Retrieved from. [www.echa.europa.eu/documents/10162/13628/raaf\\_en.pdf](http://www.echa.europa.eu/documents/10162/13628/raaf_en.pdf).
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *J. Photochem. Photobiol. B Biol.* 96 (1), 57–62.
- Ifra (International Fragrance Association), 2015. Volume of Use Survey. February 2015.
- Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J.M., 2007. Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. *Food Chem. Toxicol.* 45 (12), 2533–2562.
- Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., et al., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. *Regul. Toxicol. Pharmacol.* 62 (1), 160–182.
- Na, M., Ritacco, G., O'Brien, D., Lavelle, M., Api, A., Basketter, D., 2020. Fragrance skin sensitization evaluation and human testing, dermatitis. <https://doi.org/10.1097/DER.0000000000000684>. November 16, 2020. Volume Publish Ahead of Print Issue. Retrieved from.
- Oecd, 2015. Guidance Document On the Reporting Of Integrated Approaches To Testing And Assessment (IATA). ENV/JM/HA(2015)7. Retrieved from. <http://www.oecd.org/>.
- Oecd, 2018. The OECD QSAR Toolbox, v3.2-4.2. Retrieved from. <http://www.qsartoolbox.org/>.
- RIFM (Research Institute for Fragrance Materials, Inc), 1973a. Repeated Insult Patch Test with Isolongifolanone (Isolongifolene Ketone) (Picomate). RIFM, Woodcliff Lake, NJ, USA. Unpublished report from International Flavors and Fragrances. RIFM report number 54565.
- RIFM (Research Institute for Fragrance Materials, Inc), 1973b. Repeated Insult Patch Test with Isolongifolanone (Isolongifolene Ketone) (Piconia) in Humans. RIFM, Woodcliff Lake, NJ, USA. Unpublished report from International Flavors and Fragrances. RIFM report number 54736.
- RIFM (Research Institute for Fragrance Materials, Inc), 1977a. Report on Human Maximization Studies. Report to RIFM. RIFM Report Number 1691. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 1977b. Human Maximization Test on Isolongifolene Ketone. Unpublished report from PFW, a Division of Hercules Inc. RIFM report number 7835. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 1980. Report on Human Maximization Studies. Report to RIFM. RIFM Report Number 1790. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 1982. Report on Human Maximization Studies. Report to RIFM. RIFM Report Number 1643. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 1989a. Repeated Insult Patch Test with Isolongifolanone (Isolongifolene Ketone) (Paxamber) in Humans. RIFM, Woodcliff Lake, NJ, USA. Unpublished report from International Flavors and Fragrances. RIFM report number 54714.
- RIFM (Research Institute for Fragrance Materials, Inc), 1989b. Repeated Insult Patch Test with Isolongifolanone (Isolongifolene Ketone) (Paxamber) in Humans. RIFM, Woodcliff Lake, NJ, USA. Unpublished report from International Flavors and Fragrances. RIFM report number 54715.
- RIFM (Research Institute for Fragrance Materials, Inc), 2002. Isocedranone (Cedron) 50% in White Mineral Oil: Skin Sensitisation in the guinea Pig - Magnusson and Kligman Maximisation Method. RIFM, Woodcliff Lake, NJ, USA. Unpublished report from Symrise. RIFM report number 61857.
- RIFM (Research Institute for Fragrance Materials, Inc), 2013. Report on the Testing of Isocedranone in the BlueScreen HC Assay (-/+ S9 Metabolic Activation). RIFM, Woodcliff Lake, NJ, USA. RIFM report number 66780.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014a. Exposure Survey 04. July 2014.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014b. Isolongifolanone (Isolongifolene Ketone): Bacterial Reverse Mutation Assay. RIFM, Woodcliff Lake, NJ, USA. RIFM report number 67348.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014c. Isolongifolene Ketone (Isolongifolanone): in Vitro Micronucleus Assay in Human Peripheral Blood Lymphocytes. RIFM, Woodcliff Lake, NJ, USA. RIFM report number 67610.
- RIFM (Research Institute for Fragrance Materials, Inc), 2016a. Isolongifolene Ketone: Local Lymph Node Assay (LLNA: BrdU-ELISA Method). RIFM, Woodcliff Lake, NJ, USA. Unpublished report from RIFM report number 71630.
- RIFM (Research Institute for Fragrance Materials, Inc), 2016b. Assessment of Skin Sensitization to Isolongifolene Ketone in the Mouse (Local Lymph Node Assay). Unpublished report from RIFM report number 71631. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2016c. Direct Peptide Reactivity Assay (DPRA): Test Report on Isolongifolene Ketone. Unpublished report from RIFM report number 71632. RIFM, Woodcliff Lake, NJ, USA.



- RIFM (Research Institute for Fragrance Materials, Inc), 2018. Isolongifolene Ketone: Repeated Insult Patch Test (RIPT). RIFM Report Number 73695. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2020. Updating Exposure Assessment for Skin Sensitization Quantitative Risk Assessment for Fragrance Materials. RIFM, Woodcliff Lake, NJ, USA. RIFM report number 76775.
- Roberts, D.W., Patlewicz, G., Kern, P.S., Gerberick, F., Kimber, I., Dearman, R.J., Ryan, C. A., Basketter, D.A., Aptula, A.O., 2007. Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization. *Chem. Res. Toxicol.* 20 (7), 1019–1030.
- Rogers, D., Hahn, M., 2010. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* 50 (5), 742–754.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regul. Toxicol. Pharmacol.* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regul. Toxicol. Pharmacol.* 86, 148–156.
- Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance materials for aquatic risk assessment. *Environ. Toxicol. Chem.* 21 (6), 1301–1308.
- Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D.J., Mahony, C., Schwarz, M., White, A., Cronin, M.T., 2015. A strategy for structuring and reporting a read-across prediction of toxicity. *Regul. Toxicol. Pharmacol.* 72 (3), 586–601.
- Shen, J., Kromidas, L., Schultz, T., Bhatia, S., 2014. An *in silico* skin absorption model for fragrance materials. *Food Chem. Toxicol.* 74, 164–176.
- US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2012b. The ECOSAR (ECOLOGical Structure Activity Relationship) Class Program for Microsoft Windows, v1.11. United States Environmental Protection Agency, Washington, DC, USA.